Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.

BMC Cancer · 2012 · PMC3442969 · PMID 22876876

Europe PMC DOI

hedged sentences

0.0850

closest p · 1.7× alpha

0.1200

boldest claim

The sentences

of marginal significancep = 0.085so close (0.05 < p ≤ 0.1)

These differences were of marginal significance (p = 0.085) (Figure 2 ).

also in 464 other papers

showed a trendp = 0.12not close (p > 0.1)

Patients with codon 12 mutations showed a trend towards the opposite effect: median PFS was 7.0 months under CAPOX therapy while median PFS was 9.9 months under FUFOX (HR: 0.62, p = 0.12) (Table 4 ).

also in 53,322 other papers

a strong trendno p-value reported

Moreover, there was a strong trend towards better overall survival in patients with wild type KRAS compared to all mutant KRAS patients.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.